Clarus Therapeutics
Driven by a mission to help men overcome the health-eroding symptoms of hypogonadism
Driven by a mission to help men overcome the health-eroding symptoms of hypogonadism
Clarus Therapeutics is a men's specialty pharmaceutical company founded in 2003, driven by a mission to help men overcome the health-eroding symptoms of hypogonadism. Specializing in Biotechnology and Health Care, the company is dedicated to addressing the needs of men with hypogonadism, associated with a deficiency or absence of endogenous testosterone. Backed by prominent investors including Thomas, McNerney & Partners, L.P., H.I.G. BioHealth Partners, ProQuest Investments, C-Bridge Capital Partners, LLC, BVCF Management, Ltd. and Pavilion Capital Pte Ltd., Clarus Therapeutics recently secured a $30.00MPost-IPO Equity investment on 25 April 2022. The company's commitment to making a positive impact on the lives of affected men is evident through its relentless efforts and strong financial backing. For more information, visit them at clarustherapeutics.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $30.00M | - | 25 Apr 2022 | |
| Post-IPO Equity | $15.00M | - | 03 Dec 2021 | |
| Post-IPO Equity | $25.00M | 1 |
|
10 Sep 2021 |
| Venture Round | $31.50M | 1 |
|
12 Jun 2014 |
| Debt Financing | $10.00M | 1 |
|
01 Jan 2013 |
No recent news or press coverage available for Clarus Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
